Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00337987 · FLOW

Participant flow

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma · Source last updated 2015-02-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients received six 21-day cycles of therapy, up to a maximum of 8 cycle. Each cycle comprised of denileukin diftitox plus CHOP (cyclophasphamide, doxorubicin, vincristine, prednisone)
    id
    FG000
    title
    Denileukin Diftitox/CHOP Administration
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        49
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        49
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients received six 21-day cycles of therapy, up to a maximum of 8 cycle. Each cycle comprised of denileukin diftitox plus CHOP (cyclophasphamide, doxorubicin, vincristine, prednisone)
    id
    FG000
    title
    Denileukin Diftitox/CHOP Administration
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        49
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        49
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice